Surgical Outcomes of Phacoemulsification Followed by iStent Implantation Versus Goniotomy With the Kahook Dual Blade in Patients With Mild Primary Open-angle Glaucoma With a Minimum of 12-Month Follow-up.

PURPOSE: To study surgical outcomes after combined phacoemulsification with either iStent implantation or goniotomy using the Kahook Dual Blade (KDB) with a minimum of 12 months of follow-up. PATIENTS AND METHODS: Patients with mild primary open-angle glaucoma who underwent phacoemulsification in combination with either iStent implantation or goniotomy using the KDB from 2011 to 2017 were included. RESULTS: In total, 48 eyes in the iStent group and 29 eyes in the KDB group were included with at least 12 months of follow-up. There was no difference in patient age, sex, previous surgery, preoperative or postoperative visual acuity or intraocular pressure (IOP) between the 2 groups. Mean preoperative IOP in the iStent group decreased from 17.6±4.8 to 15.9±2.9 mm Hg (P=0.01); mean preoperative IOP in the KDB group decreased from 17.4± 4.3 to 15.0±4.0 mm Hg (P=0.01). The overall percentage of IOP reduction was 14.3% in the iStent group and 12.6% in the KDB group at 12 months of follow-up. Mean topical glaucoma medication use decreased from 2.0±0.9 to 0.7±1.1 in the iStent group and from 2.2±1.0 to 1.6±1.3 in the KDB group. Multivariable linear regression accounting for age, sex, race, baseline IOP, and number of eyes treated as covariates indicated a significant reduction in IOP from baseline with both iStent (Wald χ=3.97, P=0.046) and KDB (Wald χ=4.65, P=0.031). Multivariable logistic regression accounting for age, sex, race, baseline IOP, and number of eyes treated as covariates indicated no significant difference in overall success between iStent and KDB (Z-test=0.92, P=0.359). CONCLUSIONS: Phacoemulsification in combination with either iStent implantation or goniotomy using the KDB both achieved statistical significant reduction in IOP and number of glaucoma medications at 12 months of follow-up in patients with mild primary open-angle glaucoma with no complications.

Surgical outcomes of phacoemulsification/goniosynechialysis with and without endocyclophotocoagulation in patients with chronic angle closure glaucoma.

PURPOSE: To compare surgical outcomes of patients after phacoemulsification with goniosynechialysis (phaco/GSL) versus phaco with GSL and endocyclophotocoagulation (phaco/GSL/ECP) in patients with chronic angle closure glaucoma (CACG) through 12-month follow-up. METHODS: A retrospective, nonrandomized, comparative case series was performed. Patients with CACG who underwent phaco in combination with either GSL alone (group 1) or GSL with ECP with intracameral injection of kenalog (group 2) from 2011 to 2018 were included. Group 1 included 6 eyes of 6 patients and group 2 included 11 eyes of 10 patients. All surgeries were performed by a single surgeon (RSA). Primary outcome measures included changes in intraocular pressure (IOP), visual acuity (VA), failure based on IOP (>18 or <6 mmHg at 1 year), and secondary operative procedures and complication rates. Data were analyzed using a paired two-tailed T-test. RESULTS: The mean preoperative IOP decreased from 23.5 ± 11.2 to 14.2 ± 2.4 mmHg (P < 0.0073) in group 1 and 24.4 ± 8.2 to 14.5 ± 2.7 mmHg (P < 0.0001) in group 2. The mean % IOP reduction was 33.7% in group 1 and 34.2% in group 2. The mean improvement in VA (logMAR units) was 0.24 (P = 0.085) in group 1 and 0.13 (P = 0.657) in group 2. The mean number of topical meds decreased from 2.50 ± 1.76 to 1.80 ± 1.64 in group 1 (P = 0.513) and from 2.82 ± 1.25 to 1.17 ± 0.98 in group 2 (P = 0.014). CONCLUSION: Phaco/GSL and phaco/GSL/ECP both achieve a significant reduction in IOP without the complications associated with traditional glaucoma filtration surgeries.

Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model.

PRECIS: Rabbit model studies suggested better morphology blebs with equal intraocular pressure (IOP) efficacy as a standard mitomycin C (MMC) trabeculectomy using a novel slow-release drug delivery antifibrotic system delivering small quantities of MMC and 5-fluorouracil (5-FU). PURPOSE: To evaluate 2 different concentrations of biodegradable poly(lactic-co-glycolic acid) (PLGA) system with 5-FU and MMC (ElutiGLASS) for their ability to reduce fibrosis and compare the results with standard trabeculectomy with MMC in a rabbit model. MATERIALS AND METHODS: New Zealand albino rabbits (19) were divided into 3 groups (A, B, C) and standard trabeculectomy operation was performed in the right eye of each rabbit.Group (A) had trabeculectomy with MMC (0.4 mg/mL) applied using a Weck cell sponge; (B) trabeculectomy with slow-release ElutiGLASS (0.23 mg, 5-FU/0.33 µg MMC released over 23 to 30 d); (C) trabeculectomy with rapid release ElutiGLASS (0.45 mg of 5-FU/0.65 µg MMC, released over 5 to 7 d). The rabbits were followed for 3 months before euthanasia. RESULTS: Bleb morphology, vascularity, and fibrosis were less pronounced in groups B and C when compared with group A at 3 months. Group B appears to have a lower and more diffuse bleb appearance compared with the other 2 groups with honeycomb appearance on both clinical examination and ultrasound biomicroscopy imaging with higher percentage of maintained bleb space (83%), less fibrosis than group A while maintaining the same low inflammation score as the other 2 groups on histology. At 3 months, the PLGA polymer had completely disappeared in all rabbits. There were no statistical differences in the degree of IOP reduction or histologic inflammation, among the 3 groups. CONCLUSIONS: We successfully created a sustained-release antifibrotic drug delivery system that delivered known dosage of the drugs at doses that are significantly lower than the current standard, and resulted in less fibrosis while maintaining a healthy bleb and equal reduction of IOP. TRANSLATIONAL RELEVANCE: These results are supportive of the antifibrotic effect of the slow-release drug delivery system used in conjunction with trabeculectomy, thus paving the way for human pilot studies to improve and simplify existing surgical techniques for filtering surgeries in glaucoma.

Comparison of surgical outcomes between canaloplasty and trabeculectomy with mitomycin C at 2-year follow-up: A longitudinal cohort study.

PURPOSE: To compare operative outcomes of patients after canaloplasty and trabeculectomy with mitomycin C (MMC) through 2-year follow-up. METHODS: We included 31 eyes of 31 patients with primary open-angle glaucoma (POAG) who underwent canaloplasty and 37 eyes of 37 patients with POAG who underwent trabeculectomy with MMC with 24 months of postoperative follow-up. All surgeries were performed by a single surgeon between January 2005 and May 2011. Failure was defined as intraocular pressure (IOP> 18 or <4 mmHg at 2 years), second operative procedure, or loss of light perception. Change in IOP, visual acuity (VA), glaucoma medications, and complication rates at 24 months were analyzed. RESULTS: Caucasians made up to half of the patients included in this study (58% vs. 43%) while the rest where either African Americans (32% vs. 43%) or Hispanic (10% vs. 14%) patients between the canaloplasty and trabeculectomy group. Both groups showed significant reduction in IOP from baseline at 24 months. Trabeculectomy patients had a greater mean reduction of IOP compared to canaloplasty patients (12.2 ± 12 vs. 4.7 ± 7.5, P = 0.003) and also achieved lower IOP at 24 months (12.2 ± 4.1 vs. 14.9 ± 6.0, P = 0.03). Postoperative glaucoma medication use was less in the trabeculectomy group (n = 0, interquartile range [IQR] 0-2) compared to those in whom canaloplasty was performed (n = 2, IQR 0-3, P = 0.02). VA showed no statistical change in either group over 2 years. Overall failure rates at 2 years were comparable between the two groups: 32% for trabeculectomy and 26% for canaloplasty (P = 0.6). Subgroup analysis revealed a lower failure rate in Caucasions (15%) when compared to Blacks (42%) and Hispanics/others (50%, P = 0.03). CONCLUSION: Canaloplasty and trabeculectomy both achieved significant reduction in IOP with comparable success rates. Trabeculectomy can achieve a greater reduction in IOP while requiring fewer medications however is associated with more intensive postoperative care and frequent interventions. Pigmented populations have worse outcomes compared to Caucasians.

Heterometallic 3d-4f single-molecule magnets: ligand and metal ion influences on the magnetic relaxation.

Six tetranuclear 3d­4f single-molecule magnet (SMM) complexes formed using N-n-butyldiethanolamine and N-methyldiethanolamine in conjunction with ortho- and para-substituted benzoic acid and hexafluoroacetoacetone ligands yield two families, both having a butterfly metallic core. The first consists of four complexes of type {Co2(III)Dy2(III)} and {Co2(III)Co(II)Dy(III)} using N-n-butyldiethanolamine with variation of the carboxylate ligand. The anisotropy barriers are 80 cm­1, (77 and 96 cm­1­two relaxation processes occur), 117 and 88 cm­1, respectively, each following a relaxation mechanism from a single DyIII ion. The second family consists of a {Co2(III)Dy2(III)} and a {Cr2(III)Dy2(III)} complex, from the ligand combination of N-methyldiethanolamine and hexafluoroacetylacetone. Both show SMM behavior, the Co(III) example displaying an anisotropy barrier of 23 cm­1. The Cr(III) complex displays a barrier of 28 cm­1, with longer relaxation times and open hysteresis loops, the latter of which is not seen in the Co(III) case. This is a consequence of strong Dy(III)­Cr(III) magnetic interactions, with the relaxation arising from the electronic structure of the whole complex and not from a single DyIII ion. The results suggest that the presence of strong exchange interactions lead to significantly longer relaxation times than in isostructural complexes where the exchange is weak. The study also suggests that electron-withdrawing groups on both bridging (carboxylate) and terminal (ß-diketonate) ligands enhance the anisotropy barrier.

Sphenoid sinus dehiscence as a risk for visual consequences in an immunocompromised patient.

Isolated sphenoid sinus disease is a rare entity with severe and potentially life threatening sequela. Because of the proximity of the sinus to the orbit, anatomical defects within the surrounding bony structures can facilitate communication with orbital content, predisposing the patient to substantial visual consequences. We report a case of a 51-year-old immunocompromised male who presented with headache and gradual unilateral decreases in vision. Computed tomography revealed opacification of the left sphenoid sinus accompanied by unusual bony dehiscence of the proximal optic canal. Early recognition and treatment of sphenoid sinusitis requires urgent surgical intervention with delay of treatment potentially leading to irreversible blindness or other devastating consequences. Bony dehiscence of the sphenoid sinus overlying the optic nerve has only been found in 4% of cadavers. It is associated with increased risk of orbital complications and predicts a poor prognosis. Immediate intervention is particularly important in immunocompromised individuals who are at greater risk of these severe complications.

Orbital solitary fibrous tumor: a case series with review of the literature.

PURPOSE: To report the clinical features, patient demographics, management, and outcomes of a series of patients with orbital solitary fibrous tumors (OSFTs) and provide a review of the English literature describing this rare entity. DESIGN: A review of patient demographics, clinical presentations, imaging, histopathology, surgical management, and outcomes were analyzed. METHODS: A non-comparative retrospective chart review of the demographics, clinical presentations, imaging, histopathological features, management, and disease outcomes of patients presenting to a tertiary orbital center with a tissue diagnosis of OSFT between 2007-2012 was performed along with a review of the English-language literature. RESULTS: Our study included four male patients, with a mean age of 48 years at referral. The most common presentations included a slowly growing mass, globe displacement, diplopia on extreme gazes, and/or facial disfiguration. All tumors were analyzed with histopathology and immunohistochemistry. Treatment involved the complete surgical excision of the lesion, obtaining clear margins. All patients remain alive and well with no evidence of recurrence after a minimum follow-up of 15 months (range 15 months-5 years). CONCLUSION: SFTs should be considered when confronting a painless slowly growing orbital mass that induces globe displacement and/or facial deformity. Imaging will show a well-defined lesion that enhances with contrast. A careful initial surgical excision with clear margins is required for adequate local control of the tumor, avoiding recurrence and potential malignant transformation.